These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26001026)

  • 1. Acceptability of drug detection monitoring among participants in an open-label pre-exposure prophylaxis study.
    Koester KA; Liu A; Eden C; Amico KR; McMahan V; Goicochea P; Hosek S; Mayer KH; Grant RM
    AIDS Care; 2015; 27(10):1199-204. PubMed ID: 26001026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.
    Gandhi M; Glidden DV; Mayer K; Schechter M; Buchbinder S; Grinsztejn B; Hosek S; Casapia M; Guanira J; Bekker LG; Louie A; Horng H; Benet LZ; Liu A; Grant RM
    Lancet HIV; 2016 Nov; 3(11):e521-e528. PubMed ID: 27658870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension.
    Glidden DV; Amico KR; Liu AY; Hosek SG; Anderson PL; Buchbinder SP; McMahan V; Mayer KH; David B; Schechter M; Grinsztejn B; Guanira J; Grant RM
    Clin Infect Dis; 2016 May; 62(9):1172-7. PubMed ID: 26797207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
    Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
    BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.
    Bardon AR; Simoni JM; Layman LM; Stekler JD; Drain PK
    AIDS Res Ther; 2020 Aug; 17(1):50. PubMed ID: 32762713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
    Castillo-Mancilla J; Seifert S; Campbell K; Coleman S; McAllister K; Zheng JH; Gardner EM; Liu A; Glidden DV; Grant R; Hosek S; Wilson CM; Bushman LR; MaWhinney S; Anderson PL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6692-6697. PubMed ID: 27572401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study.
    Martin M; Vanichseni S; Suntharasamai P; Sangkum U; Mock PA; Chaipung B; Worrajittanon D; Leethochawalit M; Chiamwongpaet S; Kittimunkong S; Gvetadze RJ; McNicholl JM; Paxton LA; Curlin ME; Holtz TH; Samandari T; Choopanya K;
    Lancet HIV; 2017 Feb; 4(2):e59-e66. PubMed ID: 27866873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility, Acceptability, and Adherence with Short-Term HIV Preexposure Prophylaxis in Female Sexual Partners of Migrant Miners in Mozambique.
    Lahuerta M; Zerbe A; Baggaley R; Falcao J; Ahoua L; DiMattei P; Morales F; Ramiro I; El-Sadr WM
    J Acquir Immune Defic Syndr; 2017 Dec; 76(4):343-347. PubMed ID: 28777264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring.
    Gandhi M; Glidden DV; Liu A; Anderson PL; Horng H; Defechereux P; Guanira JV; Grinsztejn B; Chariyalertsak S; Bekker LG; Grant RM;
    J Infect Dis; 2015 Nov; 212(9):1402-6. PubMed ID: 25895984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.
    Zhang Y; Clarke W; Marzinke MA; Piwowar-Manning E; Beauchamp G; Breaud A; Hendrix CW; Cloherty GA; Emel L; Rose S; Hightow-Weidman L; Siegel M; Shoptaw S; Fields SD; Wheeler D; Eshleman SH
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study.
    Amico KR; Mehrotra M; Avelino-Silva VI; McMahan V; Veloso VG; Anderson P; Guanira J; Grant R;
    AIDS Behav; 2016 Jul; 20(7):1535-40. PubMed ID: 26992393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial.
    van der Straten A; Mayo A; Brown ER; Amico KR; Cheng H; Laborde N; Marrazzo J; Torjesen K
    AIDS Behav; 2015 May; 19(5):770-83. PubMed ID: 25384907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project.
    Spinelli MA; Glidden DV; Anderson PL; Gandhi M; McMahan VM; Defechereux P; Schechter M; Veloso VG; Chariyalertsak S; Guanira JV; Bekker LG; Buchbinder SP; Grant RM
    AIDS Res Hum Retroviruses; 2019 Sep; 35(9):788-793. PubMed ID: 31119944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project.
    Spinelli MA; Glidden DV; Rodrigues WC; Wang G; Vincent M; Okochi H; Kuncze K; Mehrotra M; Defechereux P; Buchbinder SP; Grant RM; Gandhi M
    AIDS; 2019 Apr; 33(5):867-872. PubMed ID: 30649051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maximizing the Benefits of HIV Preexposure Prophylaxis.
    Buchbinder SP
    Top Antivir Med; 2018 Apr; 25(4):138-142. PubMed ID: 29689539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting.
    Montgomery MC; Oldenburg CE; Nunn AS; Mena L; Anderson P; Liegler T; Mayer KH; Patel R; Almonte A; Chan PA
    PLoS One; 2016; 11(6):e0157742. PubMed ID: 27333000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.
    Dickinson L; Yapa HM; Jackson A; Moyle G; Else L; Amara A; Khoo S; Back D; Karolia Z; Higgs C; Boffito M
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6080-6. PubMed ID: 26195515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.